Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo

Endometrial cancer is the most common gynecologic malignancy in developed countries. The antibody–drug conjugate (ADC) sacituzumab govitecan (SG) targets trophoblast cell‐surface antigen‐2 (Trop‐2) – a cell‐surface glycoprotein highly expressed in many epithelial tumors – and delivers the active met...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Oncol
Hlavní autoři: Perrone, Emanuele, Manara, Paola, Lopez, Salvatore, Bellone, Stefania, Bonazzoli, Elena, Manzano, Aranzazu, Zammataro, Luca, Bianchi, Anna, Zeybek, Burak, Buza, Natalia, Tymon‐Rosario, Joan, Altwerger, Gary, Han, Chanhee, Menderes, Gulden, Huang, Gloria S., Ratner, Elena, Silasi, Dan‐Arin, Azodi, Masoud, Hui, Pei, Schwartz, Peter E., Scambia, Giovanni, Santin, Alessandro D.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7053235/
https://ncbi.nlm.nih.gov/pubmed/31891442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12627
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky